Key clinical point: A novel drug improved myocardial contractility and left atrial volume and function in the setting of heart failure with reduced ejection fraction.
Major finding: The left atrial function index improved by a placebo-corrected 23% in response to danicamtiv.
Study details: This was a phase 2a, randomized, double-blind, 7-day, placebo-controlled clinical trial in 40 patients with heart failure with reduced ejection fraction.
Disclosures: The danicamtiv study was sponsored by MyoKardia. The presenter reported receiving research funding from and serving as a consultant to MyoKardia and numerous other companies.
Voors AA. ESC Heart Failure 2020